TScan Therapeutics, Inc. financial data

Symbol
TCRX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
880 Winter Street, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 766 % +13.7%
Debt-to-equity 57.4 % -27.5%
Return On Equity -60.1 % +0.86%
Return On Assets -38.2 % -12.8%
Operating Margin -4.79K % -978%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 202B USD +270608%
Weighted Average Number of Shares Outstanding, Basic 112M shares +70.7%
Weighted Average Number of Shares Outstanding, Diluted 112M shares +70.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.82M USD -86.6%
Research and Development Expense 107M USD +21.8%
General and Administrative Expense 30.3M USD +14.9%
Operating Income (Loss) -135M USD -44.3%
Net Income (Loss) Attributable to Parent -127M USD -42.9%
Earnings Per Share, Basic -1.14 USD/shares +16.2%
Earnings Per Share, Diluted -1.14 USD/shares +16.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 179M USD +34%
Marketable Securities, Current 111M USD +89.9%
Accounts Receivable, after Allowance for Credit Loss, Current 31.9M USD
Assets, Current 293M USD +50.7%
Property, Plant and Equipment, Net 7.24M USD -6.46%
Operating Lease, Right-of-Use Asset 64.4M USD +1.36%
Assets 371M USD +36.4%
Accounts Payable, Current 4.28M USD +80.2%
Employee-related Liabilities, Current 6.85M USD +25%
Liabilities, Current 36M USD +20.6%
Operating Lease, Liability, Noncurrent 60.7M USD +2.7%
Other Liabilities, Noncurrent 135K USD
Liabilities 130M USD +7.31%
Accumulated Other Comprehensive Income (Loss), Net of Tax 51K USD
Retained Earnings (Accumulated Deficit) -375M USD -51.5%
Stockholders' Equity Attributable to Parent 241M USD +59.7%
Liabilities and Equity 371M USD +36.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.3M USD -24.1%
Net Cash Provided by (Used in) Financing Activities 258K USD
Net Cash Provided by (Used in) Investing Activities 36.2M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 7.15M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 184M USD +32.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 758K USD +2.02%
Deferred Tax Assets, Valuation Allowance 122M USD +47.8%
Operating Lease, Liability 65.3M USD +4.69%
Depreciation 1.25M USD -16.3%
Payments to Acquire Property, Plant, and Equipment 705K USD -15.9%
Lessee, Operating Lease, Liability, to be Paid 94.1M USD -1.9%
Property, Plant and Equipment, Gross 25.9M USD +16.1%
Operating Lease, Liability, Current 4.57M USD +40.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13M USD +23.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.1M USD +6.12%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 28.8M USD -14.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13.3M USD +21.8%
Deferred Tax Assets, Operating Loss Carryforwards 31.3M USD +35%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 13.7M USD +21.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 139M USD +39.7%
Interest Expense 3.65M USD -2.82%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%